The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study  by Ferreira, Paulo Roberto Abrão et al.
OT
a
C
s
P
C
T
M
a
b
c
d
e
f
g
h
i
S
j
k
a
A
R
A
A
K
I
R
H
H
H
h
1b r a z j i n f e c t d i s . 2 0 1 5;1 9(1):15–22
The Brazilian Journal of
INFECTIOUS  DISEASES
www.elsev ier .com/ locate /b j id
riginal Article
he clinical  effectiveness  of pegylated  interferon
nd ribavirin  for  the  treatment  of  chronic  hepatitis
 in  HIV-infected  patients  in Brazil:  a  multicentric
tudy
aulo Roberto Abrão Ferreiraa,∗, Mariliza Henrique da Silvab,c,
arlos Eduardo Brandão-Melod, Rosamar Eulira Rezendee, Mário Gonzalez f,
ânia  Reuterg, Jose David Urbaezh, Reinaldo Jose Gianini i, Ana Martinelli j,
aria Cássia Mendes-Correak
Disciplina de Infecologia Universidade Federal de São Paulo – UNIFESP, São Paulo, Brazil
Centro de Referência e Tratamento DST-AIDS de São Paulo, São Paulo, Brazil
Clínica de Especialidades de São Bernardo do Campo, São Paulo, Brazil
Universidade Federal do Estado do Rio de Janeiro – UNIRIO, Rio de Janeiro, Brazil
Centro de Especialidades – Ambulatório de Hepatites, Secretaria Municipal de Saúde de Ribeirão Preto, São Paulo, Brazil
Instituto de Infectologia Emilio Ribas, São Paulo, Brazil
Disciplina de Infectologia – Universidade Federal do Espírito Santo – UFES, Vitória, Brazil
Unidade Mista de Saúde – Unimista 508/509, SES-DF, Brasília, Brazil
Laboratório de Investigac¸ão Médica em Epidemiologia e Estatística, Faculdade de Medicina da Universidade de São Paulo – FMUSP,
ão Paulo, Brazil
Divisão de Gastroenterologia da Faculdade de Medicina da Universidade de São Paulo, Ribeirão Preto, Brazil
Departamento de Doenc¸as Infecciosas e Parasitárias da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 26 May 2014
ccepted  1 August 2014
vailable  online 1 September 2014
a  b  s  t  r  a  c  t
Introduction: in Brazil, chronic hepatitis C in patients coinfected with the human immu-
nodeﬁciency  virus (HIV) is treated with pegylated interferon (Peg-IFN) and ribavirin (RBV).
However, few studies have evaluated the effectiveness of this treatment in this particular
population.  The identiﬁcation of the factors that predict sustained virological response (SVR)
under current clinical practice would enable clinicians to more accurately estimate the prob-eywords:
nterferon
ibavirin
CV
IV
ability of achieving an SVR and therefore utilize the appropriate therapeutics, especially in
the era of direct-acting antiviral (DAA) agents.
Aims: the primary aim of our study was to determine the SVR rate under current clinical
practice.  The secondary aims were as follows: (1) to determine the factors before and during
treatment  that predict SVR; and (2) to identify the causes of treatment interruption.
∗ Corresponding author at: Federal University of São Paulo – UNIFESP, Division of Infectious Disease, Outpatient Clinic to HIV and Viral
epatitis, Rua Loefgreen, 1588, Vila Clementino, São Paulo-SP, CEP 04040-002, Brazil.
E-mail address: paulo.abrao.ferreira@gmail.com (P.R.A. Ferreira).
ttp://dx.doi.org/10.1016/j.bjid.2014.08.002
413-8670/© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
16  b r a z j i n f e c t d i s . 2 0 1 5;1  9(1):15–22
Methods: within a cohort of HIV/hepatitis C virus (HCV)-coinfected patients in Brazil, we
performed a retrospective analysis of those individuals treated with Peg-IFN and RBV.
Results: among the 382 analyzed patients, SVR was observed in 118 [30.9% (95% conﬁdence
interval (CI): 26.3–35.8)], which included 25.9% (75/289) of the patients with genotypes 1
and 4 and 48.2% (41/85) of those with genotypes 2 and 3. After multivariate analyses the
independent positive predictors for SVR after treatment for chronic hepatitis C with Peg-
IFN and RBV were: absence of an AIDS-deﬁning illness (p = 0.001), HCV viral load lower than
600,000 IU/mL at the onset of treatment (p = 0.003), higher liver enzyme levels (p = 0.039) at
baseline, infection with genotypes 2 or 3 (p = 0.003), and no transient treatment interruption
(p = 0.001).
The treatment was interrupted in 25.6% (98/382) of the patients because of adverse events
(11.3%, 43/382), virologic failure (7.8%, 30/382), and dropout (6.5%, 43/382). The main adverse
events were cytopenia and psychiatric disorders.
Conclusions: in our Brazilian case series, the SVR rate under current clinical practice con-
ditions was similar to that reported in other studies. There was a correlation between an
SVR and being infected by genotypes 2 and 3, low viral load, high ALT levels at the onset
of treatment, and absence of an AIDS-deﬁning illness. Cytopenia and psychiatric disorders
were the major causes of treatment interruption. Efforts should be focused on optimizing
management of side effects and counseling to improve adherence and to keep patients on
treatment.
© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
Therapeutic decisions regarding the treatment of hepatitis
C  with pegylated interferon (Peg-IFN) and ribavirin (RBV)
in  patients coinfected with the human immunodeﬁciency
virus (HIV) are complex. Numerous factors must be consid-
ered,  such as the status of the HIV infection, the stage of
liver  ﬁbrosis, the probability of attaining sustained virologic
response (SVR), potential treatment risks, and any comorbidi-
ties.  The treatment regimen consisting of Peg-IFN and RBV
has  a high rate of ineligibility,1 an increased frequency of
adverse  events, lower rates of SVR, and more  relapses among
the  HIV/hepatitis C virus (HCV)-coinfected population com-
pared  with HCV mono-infected patients.2 The development
and  utilization of direct-acting antiviral (DAA) agents should
advance  the treatment paradigms.
Currently, Peg-IFN and RBV, in combination with new oral
DAA  agents, remain the basis of the therapeutic regimens
utilized to treat HCV genotype 1 and the other genotypes.
Treating chronic hepatitis C with DAA agents against HCV in
HIV/HCV-coinfected patients faces many  challenges, includ-
ing  drug interactions with antiretroviral (ARV) agents,3,4
increased toxicity due to the combination therapy with ARVs,
rapid  selection of HCV-resistant mutants, treatment compli-
ance  with multiple medications, and excessive pill burden.5
HCV protease inhibitors are approved for clinical use in HCV-
mono-infected patients.6–9 Recently published data reported
that  HIV/HCV-coinfected patients treated with ﬁrst wave
protease  inhibitors (telaprevir and boceprevir),10,11 second
wave  protease inhibitors (simeprevir and faldaprevir)12,13 and
polymerase  inhibitor (sofosbuvir)14,15 had higher SVR rates
compared with those treated with Peg-IFN and RBV. Based on
these data, the international guidelines recommend new DAA
for the treatment of HIV/HCV-coinfected patients.16–19Several studies have analyzed the efﬁcacy and safety of
combining Peg-IFN and RBV to treat hepatitis C in HIV-
coinfected patients. Although in randomized studies the SVR
rate  varied from 26 to 55%,20–23 the response rate reported
in  observational studies was  lower, ranging from 12 to
21%.24–27
The current recommendations for the treatment of
chronic hepatitis C with Peg-IFN and RBV are based on the
above-mentioned randomized studies, which included highly
selective  cohorts of patients without clinically signiﬁcant
comorbidities and with supervised adherence, such as assis-
tance  at reference centers, and experienced physicians. The
aim  of this study was  to assess the effectiveness of treatment
with  Peg-IFN and RBV under typical conditions, i.e., not as part
of  a research protocol and in a population of patients treated
at  several Brazilian centers, by determining the SVR rate and
the  related factors, and the frequency and causes of treatment
interruption.
Methods
Design  and  selection  of  patients
This study was a retrospective, observational, and non-
probabilistic sampling study based on a cohort that included
12  centers at various locations in Brazil. All the HIV/HCV-
coinfected patients who were  treated with at least one dose of
Peg-IFN  and RBV (48-week regimen) between January 2005 and
June  2008 and were  assisted at these centers were  included
(intention-to-treat analysis). The treatment decisions at the
centers  were based on the guidelines of the Brazilian Health
Ministry  (which followed the international recommendations
at  the time) and were at the discretion of the attending
 s . 2 0 1 5;1  9(1):15–22  17
p
c
A
E
t
a
a
s
A
T
c
w
t
m
o
t
t
(
w
a
u
o
n
(
o
m
M
s
i
S
T
p
m
c
u
v
a
v
a
s
c
R
C
T
1
m
A
ﬁ
t
Table 1 – Baseline characteristics of the study subjects.
Variables n/N %
Male gender 277/382 72.5
Age  (years)
<35  42/371 11.3
35–39  91/371 24.5
40–44  91/371 24.5
45–49  82/371 22.1
≥50  65/371 17.5
Mean  (SD); median (min–max) 42.9 (7.7); 42 (23–78)
Nadir CD4+ (cells/mm3)
<200 126/307 41.0
200–349 98/307 31.9
350–499 47/307 15.3
≥500 36/307 11.7
Mean  (SD); median (min–max) 275.7 (205.0); 249 (1–1140)
Aids-deﬁning illness 176/354 49.7
Current use of ART 335/363 92.3
Length of ART (years)
<5  87/239 36.4
5–9  104/239 43.5
≥10  48/239 20.1
Mean  (SD); median (min–max) 6.8 (3.5); 7 (0–19)
Use of AZT 141/303 46.5
CD4+  before treatment (cells/mm3)
<350 57/376 15.2
350–499 100/376 26.6
≥500  219/376 58.2
Mean  (SD); median (min–max) 600.0 (287.2); 538 (134–2473)
HCV genotype
1  or 4 293/374 76.7
2  or 3 81/374 23.3
HCV  viral load (IU/mL) ≥600,000 164/239  68.6
ALT  levels
Normal 77/367 21.0
Above the ULNRa 290/367 79.0
METAVIR ﬁbrosis stage
0  13/357 3.6
1  101/357 28.3
2  126/357 35.3
3  72/357 20.2
4  45/357 12.6
METAVIR score of inﬂammatory activity
0  8/353 2.3
1  79/353 22.4
2  152/353 43.1
3  114/353 32.3
Cirrhosis 43/364 11.8
Steatosis 115/264 43.6
Siderosis 64/254 25.2
Type  of pegylated interferon
Alpha-2b  169/382 44.2
Alpha-2a 213/382 55.8
Length of HCV treatment (weeks)
<48  132/274 48.2
≥48  142/274 51.8
Mean  (SD); median (min–max) 42.1 (15.4); 48 (1–111)
Use of ﬁlgrastim 71/382 18.6
Use  of erythropoietin 67/382 17.5
Transient interruption 99/382 25.9b r a z j i n f e c t d i
hysicians. This study was  approved by the research ethics
ommittees at all of the participating centers.
ssessment  of  effectiveness
ffectiveness was  determined based on virological response at
he end of the treatment (HCV-RNA undetectable or <50 IU/mL)
nd  on SVR (HCV-RNA undetectable or <50 IU/mL 24 weeks
fter  the end of the treatment). Only intention-to-treat analy-
is  was  considered.
nalyzed  variables
he variables selected for analysis were  grouped into several
ategories:  variables related to the patients (age, gender, and
eight),  variables related to HCV infection [level of alanine
ransaminase (ALT) before treatment, quantitative HCV-RNA
easurements before treatment, HCV genotype, and pattern
f  liver ﬁbrosis], variables related to HCV treatment [number of
reatments  received; type, dose, and length of Peg-IFN and RBV
reatment; and frequency and causes of transient interruption
interruption of RBV and/or Peg-IFN, up to a maximum of two
eeks)  and treatment discontinuation (interruption of RBV
nd/or  Peg-IFN treatment prior to the completion of the sched-
led  48 weeks)], and variables related to HIV infection [history
f  acquired immunodeﬁciency syndrome (AIDS)-deﬁning ill-
ess, length of antiretroviral therapy (ART), use of zidovudine
AZT),  number of CD4+ T cells before treatment, and number
f  nadir CD4+ T cells].
We  reported the liver biopsy results (the degree of inﬂam-
atory  activity and the stage of ﬁbrosis) as deﬁned by the
ETAVIR  Cooperative Study Group.28 In addition, the degree of
teatosis  and siderosis were  determined by histological exam-
nation  of the liver.
tatistical  analysis
he qualitative variables were expressed as frequencies and
ercentages,  and the quantitative variables were reported as
easures of central tendency. For the binary outcomes, the
orrelation  between exposure and outcome was  estimated
sing  the prevalence ratio (PR).29,30 The variables with a p-
alue  < 0.25 by univariate analysis were selected for a multiple
nalysis  of variance using a Cox regression model with robust
ariance.31 The variables with a p-value < 0.05 in the multiple
nalysis remained in the ﬁnal model. Finally, the PR of each
uch  variable was  estimated together with the corresponding
onﬁdence interval (95% CI) at a 5% descriptive level.
esults
haracterization  of  the  population  sample
his study included 382 HIV-HCV-coinfected patients from
2  different Brazilian institutions. Most of the patients were
ale  (72.5%), 40 years old or older (64.2%), had no history of
IDS-deﬁning illness (50.3%), were on ART (92.3%) for at least
ve  years (63.6%), and had 500 or more  CD4+ T cells/mm3 in
he  peripheral blood before treatment (58.2%) (Table 1). The
Treatment discontinuation 98/382 25.6
a ULNR: upper limit of the normal range.
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Table 2 – Reasons for transient interruption or early treatment discontinuation.
Reasona Treatment discontinuation (N = 98) Transient interruption (N = 99)
N % N %
Anemia 23 23.5 47  47.5
Neutropenia 20  20.4 35  35.4
Dropout 23 23.5
Non-responders 30 30.6 – –
Psychiatric illness 21 21.4 7 7.1
Thrombocytopenia 7 7.1 6 6.1
Intolerance to medication 21 21.4 5 5.1
Incorrect use of medication 1 1.0 3 3.0
Lack of medication 1 1.0 – –
Liver decompensation 6 6.1 2 2.0
Neoplasia 2 2.0 1 1.0
Myalgia – – 1 1.0
Weight loss – – 1 1.0
Opportunistic disease 5 5.1 – –
DVT (deep vein thrombosis) 3 3.1 – –
Thyroid disorder 2 2.0 – –
CD4 reduction 1 1.0 – –
Pancreatitis 1  1.0 –  –
Kidney failure (proteinuria) 1  1.0 –  –
Drug-induced skin disorders 1 1.0 – –
Death 1 1.0 – –
Others – – 1 1.0a Some patients exhibited more than one reason.
average weight of the patients was  68.4 kg [standard deviation
(SD)  = 12.4 kg].
Regarding the HCV infection, 76.7% of the patients
had genotypes 1 or 4, 68.6% presented with a viral load
>600,000 IU/mL, and 79.0% exhibited ALT levels above the
upper  limit of the normal range (Table 1).
According to liver histopathological assessment before
treatment, the cohort included patients with advanced ﬁbrosis
(F3)  (20.2%), cirrhosis (12.6%), moderate or intense inﬂamma-
tory  activity (75.4%), some degree of steatosis (43.6%), and
some  degree of siderosis (25.2%).
It is noteworthy that 77 (21.5%) patients had previously
received anti-HCV treatment consisting of conventional inter-
feron  and RBV.
For  the current anti-HCV treatment, most patients were
given  Peg-IFN-alpha-2a (55.8%), and the median length of
treatment  was  48 weeks (n = 274). Overall, 18.6% of the patients
received  ﬁlgrastim, and 17.5% took erythropoietin.
Transient interruption or early treatment discontinuation
occurred among 99 (25.9%) and 98 (25.6%) patients, respec-
tively.
In  25.6% of the patients (98/382), the treatment was discon-
tinued  prematurely because of adverse events (11.3%, 43/382),
virologic  failure (7.8%, 30/382), and dropout (6.5%, 25/382). The
most  frequent reasons for early treatment discontinuation
among 98 patients were  as follows: nonresponse to treatment
(n  = 30; 30.6%), anemia (n = 23; 23.5%), dropout (n = 23; 23.5%),
intolerance to the medication (n = 21; 21.4%), and psychiatric
illness  that contra-indicated treatment (n = 17; 17.3%). The
most  frequent reasons for transient interruption included the
following:  anemia (n = 47; 47.5%), neutropenia (n = 47; 35.4%),
and  poor adherence (n = 10; 10.1%) (Table 2). Some patients had
more  than one cause of interruption.Among the 382 analyzed patients, 118 patients achieved
SVR  [30.9% (95% CI: 26.3–35.8)]. Among them 25.9% (75/289)
had  genotypes 1 or 4 and 48.2% (41/85) had genotypes 2 or 3.
Univariate  analysis
We conducted a univariate analysis to test the association
of  each variable and SVR. SVR was associated to: absence
of  AIDS-deﬁning illness (p < 0.001), no current use of AZT
(p  = 0.029), HCV genotypes 2 or 3 (p < 0.001), baseline HCV viral
load  lower than 600,000 IU/mL (p = 0.017), higher ALT level at
baseline  (p = 0.024, use of Peg-IFN-alpha-2a (p = 0.044), 48-week
treatment  duration (p = 0.008), and no treatment interruption
(p  = 0.005) or discontinuation (p < 0.001) (Table 3).
Multivariate  analysis
According to the multivariate analysis the following vari-
ables  correlated with SVR: absence of AIDS-deﬁning illness
(p  = 0.001), HCV viral load lower than 600,000 IU/mL at the onset
of  treatment (p = 0.003), higher liver enzyme levels (p = 0.039),
infection  with genotypes 2 or 3 (p < 0.003), and no transient
treatment interruption (p = 0.001) (Table 4).
Discussion
According to our data, infection with genotypes 2 or 3, low
pre-treatment HCV viral load, and higher transaminases at
baseline  were independent positive predictors of SVR. These
factors  were identiﬁed in previous studies, and our study
conﬁrms their relevance in clinical practice.32–36 In addition,
a  previous history of opportunistic infections and transient
b r a z j i n f e c t d i s . 2 0 1 5;1  9(1):15–22  19
Table 3 – Univariate analysis of the factors associated with SVR.
Variables With SVR, n (%) Without SVR, n (%) PR 95% CI p-value
Gender 0.077
Female 80 (76.2) 25 (23.8) 1
Male 184 (66.4) 93 (33.6) 1.41 0.96–2.06
Age*  0.442
<35 27 (64.3) 15 (35.7) 1
35–39 62 (68.1) 29 (31.9) 0.89 0.54–1.48
40–44  67 (73.6) 24 (26.4) 0.74 0.43–1.26
45–49  52 (63.4) 30 (36.6) 1.02 0.62–1.68
50  or + 49 (75.4) 16 (24.6) 0.69 0.38–1.24
Nadir  CD4** 0.403
< 200 80  (63.5) 46  (36.5) 1
200–349 71 (72.5) 27 (27.5) 0.75 0.51–1.12
350–499  28 (59.6) 19 (40.4) 1.11 0.73–1.68
500  or + 24 (66.7) 12 (33.3) 0.91 0.54–1.53
Opportunistic infection*** <0.001
Yes 137 (77.8) 39 (22.2) 1
No 106 (59.6) 72 (40.4) 1.83 1.31–2.54
Use  of ARV+ 0.599
No 18 (64.3) 10 (35.7) 1
Yes 231 (69.0) 104 (31.0) 0.87 0.52–1.47
Length  of ARV++ (years) 0.350
<5 57 (65.5) 30 (35.5) 1
5–9 68 (65.4) 36 (34.6) 1.00 0.68–1.49
10  or + 37 (77.1) 11 (22.9) 0.66 0.37–1.21
Use  of AZT+++ 0.029
Yes 108 (76.6) 33 (23.4) 1
No 105 (64.8) 57 (35.2) 1.50 1.04–2.17
Pretreatment CD4 0.441
<350  39 (68.4) 18 (31.6) 1
350–499 74 (74.0) 26 (26.0) 0.82 0.50–1.37
500  or + 146 (66.7) 73 (33.3) 1.06 0.69–1.62
HCV  Genotype@ < 0.001
1–4 214 (74.1) 75 (25.9) 1
2–3 44 (51.8) 41 (48.2) 1.86 1.38–2.49
HCV  RNA@@ 0.017
≥ 600.000 121 (73.8) 43 (26.2) 1
< 600.000 44 (58.7) 31 (41.3) 1.58 1.09–2.29
ALT@@@ 0.024
Normal 48 (62.3) 29 (37.7) 1
ULNR 208 (71.7) 82 (28.3) 0.50 0.30–0.83
Fibrosis  stage+ 0.141
3 or 4 89 (76.1) 28 (23.9) 1
0, 1 or 2 164 (68.3) 76 (31.7) 1.32 0.91–1.92
Inﬂammatory activity++ 0.065
2 or 3 195 (73.3) 71 (26.7) 1
0 or 1 55 (63.2) 32 (36.8) 1.38 0.98–1.94
Cirrhosis+++ 0.335
Yes 33 (76.7) 10 (23.3) 1
No 223 (69.2) 99 (30.8) 1.32 0.75–2.33
Steatosis++++ 0.644
Yes 78 (67.8) 37 (32.2) 1
No 105 (70.5) 44 (29.5) 0.92 0.64–1.32
Siderosis+++++ 0.340
Yes 47 (73.4) 17 (26.6) 1
No 127 (68.8) 63 (33.2) 1.25 0.79–1.97
Retreatment& 0.753
Yes 52 (67.5) 25 (32.5) 1
No 195 (69.4) 86 (30.6) 0.94 0.65–1.36
Type  of Peg interferon 0.044
Alpha 2b 126 (74.6) 43 (25.4) 1
Alpha 2a 138 (64.8) 75 (35.2) 1.38 1.01–1.90
Length  of HCV treatment (weeks)&&& 0.008
<48 102 (77.3) 30 (22.7) 1
≥48 88 (62.0) 54 (38.0) 1.67 1.15–2.44
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– Table 3 (Continued)
Variables With SVR, n (%) Without SVR, n (%) PR 95% CI p-value
Use of ﬁlgrastim 0.589
Yes 51  (71.8) 20 (28.2) 1
No 213 (68.5) 98 (31.5) 1.12 0.74–1.68
Use of erythropoetin 0.840
Yes 47 (70.1) 20 (29.9) 1
No 217 (68.9) 98 (31.1) 1.04 0.70–1.56
Weight (kg)&&& 0.149
< 70 157 (72.3) 60 (27.7) 1
≥ 70 102 (65.4) 54 (34.6) 1.25 0.92–1.70
Transient interruption&&& 0.005
Yes 80 (80.8) 19 (19.2) 1
No 176 (64.2) 98 (35.8) 1.86 1.21–2.88
Treatment discontinuation&&&& <0.001
Yes 89 (90.8) 9 (9.2) 1
No 172 (62.1) 105 (37.9) 4.13 2.17–7.84
Missing values: (*)11; (**)75; (***)28; (****)19; (#)143; (##)79; (###)6; (@)8; (@@)143; (@@@)15; (+)25; (++)29; (+++)17; (++++)118; (+++++)128; (&)24; (&&)108; (&&&)9;
(&&&&)7.
PR: prevalence ratio; AZT: zidovudine.
treatment interruption robustly correlated with treatment
failure,  which possibly reﬂects previous more  intense impair-
ment  of immune system and problems with adverse events
and  adherence, respectively. The identiﬁcation of these fac-
tors  is important to estimate the chance of SVR before and
during  treatment.
Anemia was  the primary cause for interrupting anti-HCV
treatment (23.5%) and also stood out as the main cause of
transient  treatment interruption (47.5%). Interestingly, 46.5%
of  the patients included in our study took zidovudine (AZT) at
some point of treatment. Currently, AZT is not recommended
to  be used in combination with RBV because of the high risk
of  anemia, which necessitates reducing or interrupting RBV.
Along  with previously published data, our results corroborate
the  evidence indicating that the combination of AZT and RBV
is  not appropriate.
Our  study also identiﬁed psychiatric disorder as an
important cause of treatment interruption (17.3%), which
highlights the need for more  adequate and speciﬁc interven-
tions  concerning the mental health of the target population
to  improve treatment adherence. Other important reasons
for  discontinuation of treatment were  neutropenia (20.4%),
Table 4 – Variables elected from uni- to multivariate analyses o
Variables Un
PR 95
Previous opportunistic infection (yes vs. no) 1.83 1.3
Use of AZT (yes vs. no) 1.50 1.0
HCV genotype (1 or 4 vs. 2 or 3) 1.86 1.3
HCV viral load (≥600,000 vs. <600,000 IU/mL) 1.58 1.0
Increased ALT ULNR vs. normal ALT 0.50 0.3
Type of Peg-IFN (alpha-2b vs. alpha-2a) 1.38 1.0
Length of anti-HCV treatment (<48 vs. ≥48 weeks) 1.67 1.1
Transient interruption (yes vs. no) 1.86 1.2
PR: prevalence ratio; PRadj: adjusted prevalence ratio.thrombocytopenia (7.1%), liver decompensation (6.1%), and
opportunistic  disease (5.1%).
The high rate of treatment interruption in our study is a
particular  concern in DAAs era. Even with important increase
of  SVR rates with these new drugs, interferon and ribavirin will
be used, particularly in resource-poor settings due to higher
costs  of interferon free regimens. Using telaprevir or bocepre-
vir  will increase the incidence of severe adverse events. This
situation  can impact on adherence and effectiveness, espe-
cially  in real-life HCV/HIV coinfected patients, where cases
tend  to be more  severe. It is clear that we  need more  affordable
regimens with interferon and without interferon to increase
the  access of patients to treatment.
According to results of univariate analysis, premature
treatment interruption and duration of anti-HCV treatment
correlated with SVR. Nevertheless, we opted not to include
those  variables in the multivariate analysis because we
considered them to be co-linear and a reﬂection of tran-
sient  treatment interruptions stemming from virologic failure,
adverse  events, or dropout. It is clear that the probability of
curing  chronic hepatitis C is reduced under these circum-
stances.
f the factors associated with SVR.
ivariate Multivariate
% CI p value PRadj 95% CI p value
1–2.54 <0.001 2.06 1.36–3.12 0.001
4–2.17 0.029 –
8–2.49 <0.001 1.84 1.22–2.78 <0.003
9–2.29 0.017 1.76 1.20–2.58 0.004
0–0.83 0.024 0.53 0.29–0.96 0.039
1–1.90 0.044 –
5–2.44 0.008 –
1–2.88 0.005 3.32 1.59–6.90 0.001
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Our study was  a retrospective, multicenter cohort of
IV/HCV-coinfected patients followed in clinical practice sett-
ngs at 12 Brazilian centers. Although retrospective studies
annot  replace prospective randomized studies, they repre-
ent  an important source of data on treatments in realistic
ettings. In particular, such studies provide an opportunity to
stablish whether the success rates, SVR in this case (efﬁcacy),
eported  in randomized clinical trials extend to typical treat-
ent  scenarios where the patients are exposed to factors that
re  not assessed in randomized clinical trials (effectiveness).
his information is important in pinpointing the probabil-
ty  of therapeutic success for each patient and guiding the
opulation-based decision-making by the health authorities.
herefore, observational studies should be conducted imme-
iately  following the conclusion of randomized clinical trials
o  extend the results obtained under ideal conditions to typical
ettings.37
Our study had several limitations. First, we were not able
o  establish how many  HIV/HCV-coinfected patients were
riginally  screened, i.e., were  considered to be eligible for
reatment,  or refused treatment. This consideration is critical
ecause  we cannot rule out the occurrence of selection bias,
hich  may  have favored the inclusion of patients with higher
robability  of achieving SVR.
Second, because our study was  retrospective, we did not
ave  access to all of the patients’ clinical data regarding the
nalyzed  variables. The missing data may  have impacted the
esults.  To minimize the effect of this bias on our results,
he  loss of data was  not higher than 10% for any of the vari-
bles  included in the analysis. This fact reﬂects the difference
etween randomized clinical trials, where several parameters
re  systematically collected, and typical conditions, where
nly  the most relevant parameters needed to monitor treat-
ents  are routinely collected.
Third,  because our study was  retrospective, treatment
dherence could not be monitored. However, retrospective
tudies have the advantage of assessing realistic clinical
ractice (effectiveness) without the potential bias created by
hanges in behavior that occur in prospective studies because
f  the awareness of being under observation (Hawthorne
ffect).38
In conclusion, in our study patients were  treated with
eg-IFN and RBV, and the following were  identiﬁed as pre-
ictors  of SVR: HCV genotypes 2 or 3, low HCV viral load,
igh  ALT levels at the onset of treatment, no previous his-
ory  of an AIDS-deﬁning illness and no transient treatment
nterruption. The identiﬁcation of these factors may  help cli-
icians  to estimate the probability of achieving an SVR and
herefore  make more  appropriate therapeutic decisions. The
se  of HCV new DAA in HIV/HCV-coinfected patients is cur-
ently  indicated. With these new drugs, the efﬁcacy of treating
IV/HCV-coinfected patients should increase and with less
ontra-indications and best tolerance, we will enhance the
ccess  to treatment ﬁnal effectiveness. The potential reper-
ussions  in realistic treatment settings are unknown, as the
harmacoeconomic impact, particularly in resource limited
ituation.  In many  cases, success will certainly depend on
he  appropriate management of the basic Peg-IFN and RBV
ombination therapy.
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